Sectoral Asset Management Inc Trims Holdings in Neuroderm Ltd (NDRM)
Sectoral Asset Management Inc decreased its position in Neuroderm Ltd (NASDAQ:NDRM) by 57.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 147,756 shares of the biotechnology company’s stock after selling 202,329 shares during the quarter. Sectoral Asset Management Inc owned 0.56% of Neuroderm worth $5,748,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently added to or reduced their stakes in the business. Dupont Capital Management Corp bought a new position in shares of Neuroderm during the 3rd quarter valued at approximately $1,319,000. Sphera Funds Management LTD. bought a new position in shares of Neuroderm during the 2nd quarter valued at approximately $2,228,000. Gamco Investors INC. ET AL bought a new position in shares of Neuroderm during the 3rd quarter valued at approximately $1,510,000. Havens Advisors LLC bought a new position in shares of Neuroderm during the 3rd quarter valued at approximately $1,780,000. Finally, TIAA CREF Investment Management LLC increased its position in shares of Neuroderm by 30.9% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 29,320 shares of the biotechnology company’s stock valued at $877,000 after purchasing an additional 6,920 shares during the last quarter. 52.39% of the stock is currently owned by institutional investors and hedge funds.
NDRM has been the topic of several analyst reports. Jefferies Group reissued a “buy” rating and set a $42.00 target price on shares of Neuroderm in a research report on Monday, August 14th. Zacks Investment Research raised Neuroderm from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $45.86.
Neuroderm Ltd (NASDAQ NDRM) opened at $38.85 on Friday. Neuroderm Ltd has a 12-month low of $15.20 and a 12-month high of $38.95.
Neuroderm Company Profile
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.
Receive News & Ratings for Neuroderm Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuroderm Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.